International Journal of Infectious Diseases: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14 Oct 30, 2020 COVID-19
Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab Oct 20, 2020 COVID-19
National Library of Medicine: PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice Feb 24, 2018 GvHD
Antimicrobial Agents and Chemotherapy: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults Jul 20, 2010 HIV
